Value frameworks are tools used to clarify cost-benefit tradeoffs in healthcare decisions, which means they can look very different depending on their intended audience, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.
Value frameworks are tools used to clarify cost-benefit tradeoffs in healthcare decisions, which means they can look very different depending on their intended audience, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.
Transcript (slightly modified)
There is an ever-increasing number of value frameworks: what do they get wrong and what do they get right?
The most important thing to recognize about value frameworks is that they are popping up now. Actually, since 2014, the period of 2014 to 2015, about a half a dozen what we call value frameworks emerged into great prominence here in the United States. The most important thing is that people wanted to make more explicit the tradeoffs of benefits and costs in healthcare.
Value frameworks also recognize that value is in the eye of the beholder. Different stakeholders in the healthcare system obviously have different perspectives on what comprises value. Is it effectiveness and efficacy? Is it toxicity and adverse events? To what extent is it cost, and is it cost just of the therapy and the diagnostic itself, or is it cost savings? Is it offsets in other areas? To what extent are they long-term costs versus short-term costs?
Then there are other sorts of aspects that have come into understanding value, such as things like innovation, or are you the first therapy for an otherwise failed disease, or is this a rare condition for which this is a new therapy? Those different factors matter differently to different stakeholders, so again, the most important thing about the value frameworks is that we’re actually trying to define and assess value.
Now, as of now, they all have strengths and weaknesses, and frankly the main strengths and weaknesses are that they look different from each other. That’s actually a criticism that is not really appropriate, because these value frameworks are designed by different stakeholders with different target audiences in mind, all of which have different criteria or factors that matter differently to them.
So, I’m not so much looking or caring about the weaknesses of value frameworks right now. I’m more optimistic that we will be spending some time to see how they evolve and respond to stakeholder interest. Do the target audiences find them of use or don’t they? The best thing to realize about them now is that they are continuing to evolve. Those that develop the value frameworks are, for the most part, listening and gaining feedback and tweaking along the way. That’s my look at the current and future status of value frameworks.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More